Table 1.
Patient characteristics and treatment outcomes according to the ABCG2 Q141K and V12M polymorphisms
| ABCG2 Q141K | P‐value | ABCG2 V12M | P‐value | |||||
|---|---|---|---|---|---|---|---|---|
| QK | KK | VV | VM | MM | ||||
| No. patients (%) | 69 (47.6%) | 9 (6.2%) | 71 (49.0%) | 63 (43.4%) | 11 (7.6%) | |||
| Sex (no. men/women) | 39/28 | 45/24 | 5/4 | 0.657 | 44/27 | 37/26 | 8/3 | 0.672 |
| Age (years), median (range) | 55 (17–75) | 59 (39–79) | 0.581 | 57 (17–81) | 55 (17–75) | 59 (39–79) | 0.120 | |
| Disease, n (%) | ||||||||
| Age at least 60 years | 28 (41.8%) | 30 (43.5%) | 4 (44.4%) | 0.975 | 32 (45.1%) | 22 (34.9%) | 8 (72.7%) | 0.428 |
| Stage 3, 4 | 25 (37.3%) | 24 (34.8%) | 4 (44.4%) | 0.839 | 25 (35.2%) | 39 (38.1%) | 7 (36.4%) | 0.942 |
| Elevated LDH | 35 (52.2%) | 37 (53.6%) | 4 (55.6%) | 0.976 | 36 (50.7%) | 34 (54.0%) | 7 (63.6%) | 0.714 |
| Extranodal | 9 (13.4%) | 4 (5.8%) | 2 (22.2%) | 0.166 | 9 (12.7%) | 5 (7.9%) | 1 (9.1%) | 0.661 |
| B symptoms | 11 (16.4%) | 17 (24.6%) | 1 (11.1%) | 0.385 | 17 (23.9%) | 9 (14.3%) | 3 (27.3%) | 0.310 |
| ECOG of at least 2 | 15 (22.4%) | 17 (24.6%) | 1 (11.1%) | 0.658 | 15 (21.1%) | 13 (20.6%) | 5 (45.5%) | 0.174 |
| IPI score, n (%) | 0.878 | 0.123 | ||||||
| 0–2 | 50 (74.6%) | 51 (73.9%) | 6 (66.7%) | 50 (70.4%) | 51 (81.0%) | 6 (54.5%) | ||
| 3–5 | 17 (25.4%) | 18 (26.1%) | 3 (33.3%) | 21 (29.6%) | 12 (19.0%) | 5 (45.5%) | ||
| BCL2 expression, n (%) | 0.065 | 0.719 | ||||||
| Positive | 22 (32.8%) | 17 (24.6%) | 4 (44.4%) | 20 (28.2%) | 20 (31.7%) | 3 (27.3%) | ||
| Negative | 9 (13.4%) | 14 (20.3%) | 4 (44.4%) | 12 (16.9%) | 14 (22.2%) | 1 (9.1%) | ||
| Not tested | 36 (53.7%) | 38 (55.1%) | 1 (11.1%) | 39 (54.9%) | 29 (46.0%) | 7 (63.6%) | ||
| Response, n (%) | 0.555 | 0.226 | ||||||
| CR | 47 (70.1%) | 54 (78.3%) | 8 (88.9%) | 54 (76.1%) | 47 (74.6%) | 8 (72.7%) | ||
| PR | 10 (14.9%) | 9 (13.0%) | 0 (0%) | 6 (8.5%) | 10 (15.9%) | 3 (27.3%) | ||
| SD/PD | 10 (14.9%) | 6 (8.7%) | 1 (11.1%) | 11 (15.5%) | 6 (9.5%) | 0 (0%) | ||
| ORR (CR + PR) | 57 (85.1%) | 63 (91.3%) | 8 (88.9%) | 60 (84.5%) | 57 (90.5%) | 11 (100%) | ||
| Survival, n (%) † | 0.150 | 0.826 | ||||||
| Survival | 46 (74.2%) | 56 (81.2%) | 6 (66.7%) | 54 (77.1%) | 47 (77.0%) | 7 (77.8%) | ||
| Relapse | 9 (14.5%) | 4 (5.8%) | 0 (0%) | 8 (11.4%) | 4 (6.6%) | 1 (11.1%) | ||
| Death | 7 (11.3%) | 9 (13.0%) | 3 (33.3%) | 8 (11.4%) | 10 (16.4%) | 1 (11.1%) | ||
†
Total no. cases evaluated = 140. CR, complete response; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.